Article and Video CATEGORIES

Cancer Journey

Search By

What is V20 and Why Do Radiation Dose & Field Size Matter?
Thu, 02/04/2016 - 06:00
GRACE Videos and Articles
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines the V20 standard for lung radiation and outlines the advantages of limiting dose and field size in lung radiation therapy.



These are specific questions for radiation oncology — we do tend to think about these things quite a bit. V20 is a metric we use for the normal lung tissue dose, so when we generate a radiation therapy plan, we typically contour out what normal lungs are, right and left, we subtract the tumor volume, and we call that total lung minus tumor volume, and we look at how much of that lung volume receives 20 Gy, and we like for that percentage to be less than 35% or so, because that’s been shown in patients who have a V20 below 35% have a much lower rate of radiation pneumonitis; so, that’s a metric we use. There are other metrics for that, one could look at V25 Gy, one can look at mean lung dose — there are various parameters, but V20 tends to be a good thing to look at, and that’s what we’ve used in our trials.

Now, naturally, the larger the tumor, the harder it is to achieve a V20 below 35%. Likewise, the more central a tumor, the closer it is to the hilum, the harder it is to achieve a V20 of 35%. We showed a paper yesterday, from the RTOG 0617 manuscript, where IMRT reduced lung V20 and reduced the rate of radiation pneumonitis complications in that patient population. In 0617, approximately half of the patients received IMRT, and half the patients received 3D conformal radiation therapy, and that was a stratified variable, so it was a good venue to compare the two. IMRT looks like it reduces normal lung dose, is able to deliver dose to the tumor, and reduce normal tissue toxicity.

Why does radiation dose matter? Well, this is a curative patient population, patients with Stage III or node positive disease. You can achieve a cure rate in about 25% of these patients, and one can’t achieve a cure if you don’t eradicate the local tumor. Systemic therapy is unable to do that, radiation therapy is able to do that. Studies have shown that higher doses of radiation therapy matter — the higher the dose, the greater your cell kill.

The problem comes into play when your high dose exceeds normal tissue toxicity effects. That can be a bad thing, and has shown to be a bad thing in 0617. More conformal techniques – we’re testing protons today, because protons can avoid normal tissue toxicity. We’re trying to escalate radiation dose with protons in a current phase three trial randomized called RTOG 1308. Patients are able to receive 70 Gy of chemoradiation therapy with proton beam, versus IMRT, to see if proton beam reduces normal tissue dose and perhaps improves survival.

Why does field size matter? Field size matters because you’re trying to limit your normal tissue toxicities, so you don’t want to over-treat the lung tissue, or the heart tissue, and so, the smaller the field size, the better. That correlates with how small the tumor is — the smaller the tumor, the better. That’s a pretty standard thought process.

What do you do with large tumors? You do the best you can. You treat at least to 60 Gy, use the most sophisticated techniques you can. IMRT is a good venue to try to reduce normal lung tissue doses by choosing the beam angles and beam weights to try to achieve a V20 less than 35%, and try to limit your heart V40 as much as possible.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Spanish Targeted Therapy Lung Cancer Patient Forum 2023
2023 Terapias Dirigidas en el Foro de Pacientes con Cáncer de Pulmón El vídeo completo sin editar está disponible On Demand   View HERE  
Spanish TTF 2023
Únete a nosotros, sábado 12 de agosto a las 9:00 a.m.  En este foro anual de pacientes en vivo, los principales oncólogos torácicos de todo el mundo discuten temas relevantes para los objetivos del cáncer de pulmón, así como mutaciones raras.  
Targeted Therapies in Lung Cancer Patient Forum 2023
Thank you for joining us on Saturday for the 2023 Targeted Therapies in Lung Cancer Patient Forum! The full unedited versions of the 2023 Targeted Therapies in Lung Cancer Patient Forum presentations from the Mainstage and Second Stage, are now available OnDemand. These topics will be edited and offered as shorter videos in the coming weeks.  

Forum Discussions

ONKTALK is tomorrow. 

I hope to see you there.

The forum is now available on demand here.  Don't hesitate to ask questions as they come up. 

Take care,


Hi happybluesun,  Welcome to Grace.   I'm sorry your mom is going through this. 


Driver mutations are mutations that drive (or cause) the cancer.  Having more than one driver mutation is...

Hi Janine, thank you very much for your reply. As of June 2023, my mom has been prescribed Almonertibi Mesilate Tablet, a targeted therapy medicine made by the Chinese company Haosen...

Hi happybluesun, How is your mom feeling?  Her case has specific components including the rare combo of mutations situation we can't help with a specific "this is standard of care".  She...

Recent Comments

The forum is now available…
By JanineT GRACE … on Mon, 09/25/2023 - 14:10
By JanineT GRACE … on Fri, 09/22/2023 - 15:50
Yes, all of the brand-named…
By JanineT GRACE … on Sun, 09/17/2023 - 14:43
TKI options
By happybluesun on Sun, 09/17/2023 - 10:55